It is worth mentioning that the majority of current recommendations are based on observational studies or small-scale clinical trials.ĭisease progression Mycobacterium avium complex Lung disease Nontuberculous mycobacterium Treatment.Ĭopyright © 2020. Although the burden of MAC-LD has increased over the past two decades, treatment remains difficult because of intolerance of long-term antibiotics, lack of adherence to guidelines, and disease recurrence. Although the discovery of new treatment options is warranted, adherence to guidelines remains most crucial in treating patients with MAC-LD. Mycobacterium avium complex (MAC) is the major pathologic nontuberculous mycobacteria causing lung disease (LD) in humans worldwide. Because it’s emerged that Apple will be given priority treatment by its supplier TSMC in getting deliveries of chips, according to DigiTimes and based on sources at fabless chipmakers. Without adherence, macrolide resistance can occur, which leads to poor outcomes in patients with MAC-LD. With adherence to guideline-based therapy, treatment is successful in two thirds of treatment-naïve patients without macrolide resistance. Physicians should monitor side effects in patients and maintain the regimen for 12 months, beginning from when sputum conversion has been obtained. The standard three-drug regimen should be macrolide, rifamycin, and ethambutol. Thus, physicians should consider antibiotic treatment for patients with MAC-LD and cavitary pulmonary lesions or symptomatic non-cavitary nodular bronchiectasis pattern at initial visits and also for those with clinical deterioration during follow-up. The current guidelines recommend antibiotic initiation for patients with MAC-LD and severe disease and in those with disease progression. ![]() Mycobacterium avium complex (MAC) is the major pathologic nontuberculous mycobacteria causing lung disease (LD) in humans worldwide.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |